Charl De Klerk – General Manager, Bard South Africa
26.02.2016 / Pharmaboardroom
The general manager of Bard SA, Charl De Klerk, illustrates the company’s growth ambitions within South Africa and Sub-Saharan Africa, while also depicting how Bard has adapted its therapeutic portfolio to the dynamics of South Africa and the type of pipeline innovations that will strengthen its competitive positioning in the industry.
In line with the company’s 3-year organic growth strategies, what initiatives have you pursued as GM, to expand Bard’s capabilities, scope, and presence in South Africa?
In line with Bard’s global strategy of product leadership, the current focus of my directives involves bringing Bard innovation to South Africa and the rest of Africa, especially among our key therapeutic areas: oncology, urology, general surgery, and vascular disease. Historically, Bard products were part of a distributor model, but we then bought back that relationship in 2007. So, it was really starting from mid 2000s that Bard began investing in the opportunities that South Africa had to offer. In the last four years alone, we’ve managed to double our turnover and headcount, with +/-100 staff members now working here in the South African operation.